FOXC1 and metastatic malignant neoplasm: In this review, we also highlight several potential targeted therapeutic strategies, based on utilizing already available FDA-approved oral anticancer drugs, that may help achieve improved clinical outcomes for patients diagnosed with FOXC1-overexpressing pro-metastatic cancers.